贝伐珠单抗靶向治疗联合TP方案治疗复发性或转移性宫颈癌的效果研究

Study on the Efficacy of Bevacizumab Targeted Therapy Combined with TP Regimen in the Treatment of Recurrent or Metastatic Cervical Cancer

探讨贝伐珠单抗靶向治疗联合TP方案治疗复发性或转移性宫颈癌的效果。选取2021年1月—2024年1月贵州省黔东南州人民医院收治的80例复发性或转移性宫颈癌患者为研究对象。采用随机数字表法将其分为对照组和观察组,每组各40例。对照组接受单一TP方案治疗,观察组接受贝伐珠单抗靶向治疗联合TP方案治疗,比较两组患者的治疗效果。结果显示,治疗后,观察组血清学指标SCC-Ag、CEA水平低于对照组,治疗总有效率高于对照组,不良反应总发生率低于对照组(P<0.05)。研究发现,对于复发性或转移性宫颈癌患者,联合应用贝伐珠单抗靶向治疗与TP方案的临床效果较为突出,可改善患者肿瘤发展情况,提高患者的临床疗效。同时,两种治疗方法联合使用还具有较高的安全性,治疗过程中患者的不良反应发生概率较低。

Exploring the efficacy of bevacizumab targeted therapy combined with TP regimen in the treatment of recurrent or metastatic cervical cancer.Select 80 patients with recurrent or metastatic cervical cancer admitted to Qiandongnan Prefecture People’s Hospital from January 2021 to January 2024 as the research subjects.They were divided into a control group and an observation group using a random number table method,with 40 cases in each group.The control group received single TP regimen treatment,while the observation group received bevacizumab targeted therapy combined with TP regimen treatment.The therapeutic effects of the two groups of patients were compared.The results showed that after treatment,the serum indicators SCC Ag and CEA levels in the observation group were lower than those in the control group,the total effective rate of treatment was higher than that in the control group,and the total incidence of adverse reactions was lower than that in the control group(P<0.05).Research has found that for patients with recurrent or metastatic cervical cancer,the combination of bevacizumab targeted therapy and TP regimen has significant clinical effects,which can improve tumor development and enhance clinical efficacy.Meanwhile,the combination of the two treatment methods also has high safety,and the probability of adverse reactions in patients during the treatment process is relatively low.